We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Ariad Pharmaceuticals has initiated enrollment of advanced cancer patients at
major European cancer centers in two multicenter Phase Ib clinical trials of
its novel mTOR inhibitor, AP23573, combined with the widely used chemotherapeutic
agents, paclitaxel or capecitabine.
Insmed has initiated a Phase II clinical trial examining the therapeutic benefit
of treating Type A Extreme Insulin Resistance with SomatoKine, the company's
proprietary once daily IGF-I therapy.
Genentech has announced that two Phase III trials of Herceptin were stopped
early after a preliminary joint interim analysis demonstrated an improvement
in the primary endpoint of disease-free survival and in the secondary endpoint
of overall survival.
American Pharmaceutical Partners (APP) has received approval from the FDA for
the abbreviated new drug application (ANDA) of Dexamethasone Sodium Phosphate
Injection USP, 10 mg/mL, (preserved).
Bentley Pharmaceuticals has entered into an agreement with Dong Sung Pharmaceuticals
for the development of an intranasal spray formulation of insulin for the South
Korean market and possibly additional territories.
Cardiome Pharma has successfully completed the Phase Ib study for its controlled-release
oral formulation of RSD1235 for the chronic treatment of atrial fibrillation
relapse.
Millennium Pharmaceuticals has announced, in collaboration with Johnson &
Johnson (J&J) Pharmaceutical Research & Development, the initiation
of PEAK (Prospective Evaluation of bortezomib in Adenocarcinoma with bronchioalveolar
features as a Keystone of therapy).